Chenggong Li

1.1k total citations
36 papers, 566 citations indexed

About

Chenggong Li is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Chenggong Li has authored 36 papers receiving a total of 566 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 11 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Chenggong Li's work include CAR-T cell therapy research (28 papers), Immune Cell Function and Interaction (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). Chenggong Li is often cited by papers focused on CAR-T cell therapy research (28 papers), Immune Cell Function and Interaction (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). Chenggong Li collaborates with scholars based in China, Spain and United States. Chenggong Li's co-authors include Heng Mei, Yu Hu, Yu Hu, Wenjing Luo, Huiwen Jiang, Jun Deng, Yinqiang Zhang, Lu Tang, Lisha Ai and Lin Liu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cell Death and Differentiation.

In The Last Decade

Chenggong Li

33 papers receiving 562 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chenggong Li China 12 399 247 121 106 106 36 566
Xinjie Xu United States 9 290 0.7× 160 0.6× 118 1.0× 67 0.6× 99 0.9× 35 483
Sanfang Tu China 16 582 1.5× 297 1.2× 154 1.3× 144 1.4× 201 1.9× 52 858
Changju Qu China 12 249 0.6× 318 1.3× 72 0.6× 50 0.5× 61 0.6× 38 540
Amelia M. Huehls United States 10 488 1.2× 395 1.6× 47 0.4× 52 0.5× 166 1.6× 15 704
Liora M. Schultz United States 10 347 0.9× 132 0.5× 77 0.6× 73 0.7× 202 1.9× 41 455
Brigitte Neuber Germany 16 529 1.3× 260 1.1× 169 1.4× 140 1.3× 229 2.2× 42 698
Sascha Haubner Germany 9 393 1.0× 207 0.8× 97 0.8× 50 0.5× 263 2.5× 16 614
Talía Velasco-Hernández Spain 12 358 0.9× 367 1.5× 54 0.4× 27 0.3× 125 1.2× 20 692
Katherine D. Cummins United States 8 408 1.0× 281 1.1× 147 1.2× 115 1.1× 123 1.2× 18 595
Stefanie Lesch Germany 8 686 1.7× 284 1.1× 188 1.6× 211 2.0× 278 2.6× 10 798

Countries citing papers authored by Chenggong Li

Since Specialization
Citations

This map shows the geographic impact of Chenggong Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chenggong Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chenggong Li more than expected).

Fields of papers citing papers by Chenggong Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chenggong Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chenggong Li. The network helps show where Chenggong Li may publish in the future.

Co-authorship network of co-authors of Chenggong Li

This figure shows the co-authorship network connecting the top 25 collaborators of Chenggong Li. A scholar is included among the top collaborators of Chenggong Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chenggong Li. Chenggong Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chen, Zhihan, Weijun Luo, Yun Jin Kang, et al.. (2025). Comparison of regional differences in safety and efficacy of CAR-T therapy for hematologic malignancies in a real-world setting: a systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 216. 104969–104969.
3.
Wang, Xindi, Wenjing Luo, Zhaozhao Chen, et al.. (2025). Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signature. Journal for ImmunoTherapy of Cancer. 13(6). e010822–e010822. 2 indexed citations
4.
Zhang, Cheng, Chenggong Li, Xue Li, Mao Ye, & Zhongmin Liu. (2024). A general Physics-Informed Neural Network approach for deriving fluid flow fields from temperature distribution. Chemical Engineering Science. 302. 120950–120950. 2 indexed citations
5.
Luo, Wenjing, Chenggong Li, Lu Tang, et al.. (2024). Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma. Blood. 144(Supplement 1). 3420–3420. 2 indexed citations
6.
Li, Chenggong & Heng Mei. (2024). Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?. The Lancet Haematology. 11(10). e712–e713. 2 indexed citations
7.
Luo, Wenjing, Yinqiang Zhang, Chenggong Li, et al.. (2024). BTK Inhibitor Synergizes with CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients with Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial. Blood. 144(Supplement 1). 6546–6546. 1 indexed citations
8.
Zhang, Yinqiang, Chenggong Li, Mengyi Du, et al.. (2023). Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer Journal. 13(1). 61–61. 52 indexed citations
9.
Wu, Jianghua, Wenjing Luo, Lu Tang, et al.. (2023). Dual Co-Stimulation with CD28 and ICOS Enhances T Cell Activation and Optimizes CAR-T Cell Antitumor Activity. Blood. 142(Supplement 1). 2061–2061. 1 indexed citations
10.
Mei, Heng, et al.. (2023). Quantification of ADA of Humanized CD19 CAR-T Cell Therapy in R/R LBCL. Blood. 142(Supplement 1). 6870–6870.
11.
Xu, Jia, Wenjing Luo, Chenggong Li, & Heng Mei. (2023). Targeting CD22 for B-cell hematologic malignancies. Experimental Hematology and Oncology. 12(1). 90–90. 19 indexed citations
12.
Zhang, Yinqiang, Fen Zhou, Yingnan Li, et al.. (2022). Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia. Frontiers in Immunology. 13. 914959–914959. 16 indexed citations
13.
Du, Mengyi, Linlin Huang, Haiming Kou, et al.. (2022). Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma. Frontiers in Immunology. 13. 898341–898341. 6 indexed citations
14.
Du, Mengyi, Heng Mei, Chenggong Li, et al.. (2021). Single-Cell Analyses Identify Transcriptional Characterizations of Subsets Associated with Efficacy and Toxicity for CAR-T Immunotherapy in B-ALL Patients. Blood. 138(Supplement 1). 4815–4815. 1 indexed citations
15.
Tang, Lu, Huan Zhang, Chenggong Li, et al.. (2019). Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis. BMC Cancer. 19(1). 849–849. 10 indexed citations
16.
Li, Chenggong, Heng Mei, & Yu Hu. (2019). Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. Briefings in Functional Genomics. 19(3). 175–182. 64 indexed citations
17.
Li, Chenggong, Heng Mei, Yu Hu, et al.. (2019). A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial. Blood. 134(Supplement_1). 930–930. 67 indexed citations
18.
Tang, Lu, Yizhong Peng, Chenggong Li, et al.. (2019). Prognostic and Clinicopathological Significance of MiR-155 in Hematologic Malignancies: A Systematic Review and Meta-analysis. Journal of Cancer. 10(3). 654–664. 14 indexed citations
19.
Shen, Jiaying, Chengyong Du, Danni Chen, et al.. (2017). A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance. Cell Death and Differentiation. 25(2). 406–420. 78 indexed citations
20.
Zhao, Yu, Xiumei Wu, Junya Chen, et al.. (2014). The History and Outlook of Animal Drugs Treating Asthma, Chronic Bronchitis, and Haze Episode-induced Respiratory Diseases. Macedonian Journal of Medical Sciences (University of Skopje). 3(2). 69–78. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xinjie Xu Breakdown of academic impact, for papers by Sanfang Tu Breakdown of academic impact, for papers by Changju Qu Breakdown of academic impact, for papers by Amelia M. Huehls Breakdown of academic impact, for papers by Liora M. Schultz Breakdown of academic impact, for papers by Brigitte Neuber Breakdown of academic impact, for papers by Sascha Haubner Breakdown of academic impact, for papers by Talía Velasco-Hernández Breakdown of academic impact, for papers by Katherine D. Cummins Breakdown of academic impact, for papers by Stefanie Lesch
Rankless by CCL
2026